window.pageData = {"stock":{"_id":3000000015033,"name":"国联医药消费混合型证券投资基金","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","stockCode":"015033","tickerId":15033,"shortName":"国联医药消费混合C","currency":"CNY","exchange":"jj","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":3,"status":"normal","setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":117434229.1,"setUpShares":117434229.1,"masterFundFlag":null,"activeFundFlag":null,"classificationFlag":null,"closedEnd":null,"etfFundFlag":null,"feederFundFlag":null,"indexFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"pinyin":"glyyxfhhxzqtzjj","fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50820000","tickerId":50820000,"name":"国联基金管理有限公司"},"managers":[{"name":"潘天奇","stockType":"fund_manager","stockCode":"f100000022","exchange":"fm","tickerId":162017207010}],"hotMetrics":{"fss":{"stockId":3000000015033,"type":"fss","f_s_s_d":"2024-06-29T16:00:00.000Z","f_ins_h_s_r":0.0377,"f_ind_h_s_r":0.9623,"f_h_a":4049,"f_h_s_a":15423,"f_ind_h_s_r_c_1y":-0.037699999999999956,"f_ind_h_s_r_c_hy":-0.037699999999999956,"f_ins_h_s_r_c_1y":0.0377,"f_ins_h_s_r_c_hy":0.0377,"last_data_date":"2025-12-30T16:00:00.000Z"},"fpr":{"stockId":3000000015033,"type":"fpr","f_p_r_fys_ssc":8977,"f_p_r_fys_ssrp":0.9869652406417112,"f_p_r_m1_ssc":9298,"f_p_r_m1_ssrp":0.9823599010433474,"f_p_r_m3_ssc":9145,"f_p_r_m3_ssrp":0.9757217847769029,"f_p_r_m6_ssc":8897,"f_p_r_m6_ssrp":0.9908947841726619,"f_p_r_y1_ssc":8395,"f_p_r_y1_ssrp":0.9848701453419109,"f_p_r_y2_ssc":7792,"f_p_r_y2_ssrp":0.9376203311513285,"f_p_r_y3_ssc":7012,"f_p_r_y3_ssrp":0.9496505491370704,"f_cagr_p_r_fs_ssc":9258,"f_cagr_p_r_fs_ssrp":0.939289186561521},"fp":{"stockId":3000000015033,"type":"fp","f_p_r_fys":-0.20965130087444583,"f_p_r_m1":-0.13052256532066464,"f_p_r_m3":-0.17332881662149902,"f_p_r_m6":-0.22397710409158278,"f_cagr_p_r_fs":-0.0703193531959091,"f_p_r_y1":-0.1884491741492066,"f_p_r_d1":0.0033810143042913854,"f_p_r_y2":0.002190280629706942,"f_p_r_y3":-0.2076839826839817,"last_data_date":"2026-06-17T16:00:00.000Z","f_i_d":"2022-03-08T16:00:00.000Z"},"ff":{"stockId":3000000015033,"type":"ff","f_m_f":352146,"f_m_f_r":0.012,"f_c_f":58691,"f_c_f_r":0.002,"f_m_a_c_f":410837,"f_m_a_c_f_r":0.014,"f_m_c_f_d":"2025-03-06T16:00:00.000Z","f_c_fr":0.002,"f_fr_d":"2025-03-06T16:00:00.000Z","f_m_fr":0.012,"f_mac_fr":0.014},"f_nlacan":{"stockId":3000000015033,"type":"f_nlacan","f_nv_d":"2026-06-17T16:00:00.000Z","f_nv":0.7321,"f_nv_cr":0.01694679816641198},"f_as":{"stockId":3000000015033,"type":"f_as","f_tas":22463178.791300002,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj"}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000015032,"stockId":600276,"holdings":62720,"marketCap":3463398,"netValueRatio":0.0767,"quarterlyChange":-0.07302333389289883,"stock":{"stockCode":"600276","exchange":"sh","stockType":"company","tickerId":600276,"name":"恒瑞医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000015032,"stockId":688266,"holdings":27137,"marketCap":2681135,"netValueRatio":0.0593,"quarterlyChange":0.06580366774541457,"stock":{"stockCode":"688266","tickerId":688266,"exchange":"sh","stockType":"company","name":"泽璟制药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000015032,"stockId":688192,"holdings":47912,"marketCap":2596351,"netValueRatio":0.0575,"quarterlyChange":-0.059201388888888706,"stock":{"stockCode":"688192","tickerId":688192,"exchange":"sh","stockType":"company","name":"迪哲医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000015032,"stockId":1000000000001177,"holdings":482796,"marketCap":2510817,"netValueRatio":0.0556,"quarterlyChange":-0.04692556634304246,"stock":{"stockCode":"01177","exchange":"hk","stockType":"company","tickerId":1177,"name":"中国生物制药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000015032,"stockId":2755,"holdings":153400,"marketCap":2402244,"netValueRatio":0.0532,"quarterlyChange":-0.041028781383954605,"stock":{"stockCode":"002755","exchange":"sz","stockType":"company","tickerId":2755,"name":"奥赛康"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000015032,"stockId":688382,"holdings":110552,"marketCap":2102699,"netValueRatio":0.0465,"quarterlyChange":-0.30176211453744506,"stock":{"name":"益方生物","exchange":"sh","stockType":"company","stockCode":"688382","tickerId":688382}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000015032,"stockId":600519,"holdings":1400,"marketCap":2030000,"netValueRatio":0.0449,"quarterlyChange":0.052876167240301974,"stock":{"stockCode":"600519","exchange":"sh","stockType":"company","tickerId":600519,"name":"贵州茅台"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000015032,"stockId":603259,"holdings":20200,"marketCap":1981620,"netValueRatio":0.0439,"quarterlyChange":0.08230361871138547,"stock":{"stockCode":"603259","exchange":"sh","stockType":"company","tickerId":603259,"name":"药明康德"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000015032,"stockId":1000000000001530,"holdings":72500,"marketCap":1449274,"netValueRatio":0.0321,"quarterlyChange":-0.06368899917286963,"stock":{"stockCode":"01530","exchange":"hk","stockType":"company","tickerId":1530,"name":"三生制药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000015032,"stockId":1000000000009606,"holdings":5200,"marketCap":1354445,"netValueRatio":0.03,"quarterlyChange":-0.010731052984573997,"stock":{"exchange":"hk","stockType":"company","stockCode":"09606","tickerId":9606,"name":"映恩生物-B"}}]},"list":[{"_id":"69e8ebc11398d79843fe965a","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000015032,"sao":"2026年一季度在经济增长放缓与能源冲击抬升通胀预期之间反复，美联储3月议息会议维持联邦基金利率3.5%-3.75%不变，较此前更偏鹰派，市场对年内降息定价显著后移。国内方面，经济在一季度呈现供给较强、出后较强，内需温和修复的特征，一季度国内经济具备“开门红”的基础条件，海外地缘冲突和高油价持续时间将影响二季度复苏斜率。行业层面，一季度医药板块表现分化，创新药产业链景气度较高，2026年1-3月中国创新药对外授权（海外BD）交易总包金额已超过600亿美元，接近2025年全年一半，超过2024年全年金额，整体呈现加速趋势，也是未来几年行业增长的前瞻指标。4-6月行业进入国际学术会议期间，重要临床数据将陆续读出。板块投资逻辑将从海外授权预期逐步向临床价值验证及后续商业化兑现演进。研发服务（CXO）和上游科研试剂公司订单和收入指引反映了产业投融资和研发需求回暖像产业链传导。部分院内器械板块终端需求边际变化值得重点跟踪，供给和库存优化有望让报表逐季改善。商业、服务、中药、疫苗、血制品等修复节奏相对缓慢。消费方面，服务消费和部分必选消费边际变化更为明显，修复仍以局部场景改善为主。二季度生猪养殖板块值得关注，市场往往在猪价左侧底部区域和去产能确定阶段提前布局。组合配置方向包括创新药产业链、医疗器械、生物制品、中药、医疗服务、医药商业、消费品等。我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以中长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","lastUpdated":"2026-04-22T15:39:45.755Z","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"国联医药消费混合型证券投资基金2026年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1476959","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69cac9d840924dd8ca638f28","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-03-29T16:00:00.000Z","stockId":3000000015032,"sao":"2025年医药行业创新药产业趋势向好，海外授权项目（BD）数量和金额呈现加速态势，国内处方端和零售端对产业链供给和渠道拉动效应有限。组合重点配置市场更关注的外部需求和技术创新领域。2026年随着内需复苏和产业链景气度传导，更多子行业具备较好投资机会。消费品领域终端数据需高频跟踪以确认需求恢复情况。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以中长期视角构建组合，努力为持有人创造长期回报。","lastUpdated":"2026-03-30T19:07:04.886Z","mo":"2025年美国宏观经济增长动能偏弱，消费信心减弱，通胀压力仍然存在，美联储放缓降息节奏。欧元区同时面临外部贸易政策扰动和内部结构性疲软，预计未来货币宽松空间有限。国内方面，需求恢复较缓慢，整体经济仍处于新旧切换关键时期，新质生产力持续推动经济结构优化。2026年是“十五五”规划开局之年，预计政策端将兼顾稳增长和结构平衡，财政和货币政策将协同发力助力达成目标。展望2026年，医药行业更多细分领域值得关注，我们将看到更多重磅临床数据催化以增强中国药企全球竞争力提升的认知。研发外包服务和科研上游也将伴随产业链持续改善。在兼具科技和高端制造属性的医疗器械领域，新技术赋能值得重点关注，部分器械企业布局的脑机接口处于产业化前夕，产业空间和发展前景广阔。院内器械设备在2026年也有望逐步改善。AI医疗领域，辅助诊断，大数据模型，制药，服务等细分行业也将受益于新工具降本增效。在传统服务和消费品领域，我们仍然高频跟踪动态数据，密切关注边际变化。","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"国联医药消费混合型证券投资基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1450491","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517dc0","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-27T16:00:00.000Z","stockId":3000000015032,"sao":"2025年三季度美国宏观经济仍然展现较强韧性，通胀压力尚未缓解，美联储9月会议公布降息25基点后年内有望继续下调利率。欧元区经济复苏动能较弱，主要系制造业产出拖累，预计欧洲央行在通胀目标达到合理区间前将维持谨慎货币政策。国内方面，整体需求偏弱情况下高新技术制造增长持续推动经济结构优化，政策端通过财政货币协同发力稳定预期。行业层面，医药制造业收入和利润趋势企稳。国内处方端和零售渠道需求复苏同时，供给格局得到优化。海外需求虽受到关税博弈扰动，供应链格局仍取决于产业竞争力。子行业中，创新药板块三季度有一定波动但中长期产业趋势确定，中国药企全球竞争力提升，通过海外权益授权（BD）等方式深度参与全球市场，未来会看到更多创新药产品登上舞台。研发外包服务产能优化后也将伴随产业链进入新一轮景气周期。在兼具科技和高端制造属性的医疗器械和设备领域，24年终端需求拉动放缓和行业整治行动扰动导致部分子行业25年以来三个季度消化渠道库存出厂口径表现一般，市场走势已反映了部分预期，随着需求恢复及库存改善，院内器械有望逐步改善，技术突破，进口替代和国际化趋势是驱动市场定价的核心。在医疗服务和消费品领域，我们仍然高频跟着动态数据，在消费政策支持和需求回暖带动下，更多细分新型消费和医疗服务领域也非常值得期待。组合配置方向包括创新药产业链、医疗器械、生物制品、中药、医疗服务、医药商业、消费品等。我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以中长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","lastUpdated":"2026-03-09T13:54:31.118Z","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"国联医药消费混合型证券投资基金2025年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1375293","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517dbf","date":"2025-06-29T16:00:00.000Z","stockId":3000000015032,"sao":"报告期内投资组合侧重配置相对高景气度的创新药方向，聚焦优质成长确定标的，动态调整比例来降低波动和回撤。小部分消费方向配置以相对比较优势赛道的核心龙头标的为主。组合配置方向包括创新药、创新器械，生物制品、中药、医疗服务、医药商业、消费品等。我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以中长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","declarationDate":"2025-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.114Z","mo":"2025年上半年美国宏观经济先抑后扬，企业赶在4月关税政策出台前抢进口，逆差扩大，二季度进口激增效应逐渐消退，呈现温和增长态势。6月非农就业数据超预期，美联储降息路径出现变数。欧元区经济增长依然乏力，贸易博弈增加出口不确定性。国内方面，内需较弱，期待后续较为积极的财政和货币政策。行业层面，上半年医院终端需求处于恢复过程中，创新药板块呈现较好相对表现。从政策支持，出海权益授权，部分龙头企业经营趋势持续向好，本轮产业趋势有望持续。创新药景气传导过程中，配套产业链中游和上游板块亦值得重点关注。除创新药产业链外，我们将密切关注下半年国内医院终端器械设备需求恢复情况，经历了行业集中整治和库存消化后，部分高端器械设备有望迎来新的景气周期。","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"国联医药消费混合型证券投资基金2025年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1348189","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517dbe","date":"2025-03-30T16:00:00.000Z","stockId":3000000015032,"sao":"2025年一季度美国部分宏观经济指标已出现转弱迹象，出口和消费疲软对美国经济增长形成拖累。欧元区经济仍然面临压力，通胀波动仍有不确定性。特朗普在关税政策的加码将加重市场对全球贸易萎缩担忧。国内方面，外部环境变化对经济平稳增长形成一定的挑战。我们对中国强大的产业链基础和科技潜力充满信心，财政和货币等政策工具储备可以应对变化。行业层面，开年以来部分医药子行业经营趋势呈现回暖趋势，预计需求恢复趋势有望延续。随着集采政策优化，支付端多元化及医保目录变化等推进，行业将迎来更高质量增长。我们非常看好创新药的发展，科技领域的DeepSeek以低成本和高性能的开源模型引发全球关注。中国创新药企业正在用相似的路径影响着全球的药品市场格局，经过多年的人才和技术积淀，资本投入，产业链完善，行业已经步入质变突破关键点，2024 年，CDE批准61 款创新药，包括“全球首个”和潜在“Best in class” 类药物，产业升级加速。同时，产业链配套CRO、CDMO 等专业服务机构发展迅速，为药企提供高效专业服务，助推行业效率提升。国际化进程中，重磅产品陆续通过国际认证进入欧美主流市场，多项国内研发阶段创新药通过商业权益授权方式与外资药企达成合作。2024年，国内创新药BD（Business Development）总金额创下了历史的新高，在MNC主导5000万美元以上预付款的合作中，国内项目占比大幅提升，这些项目达成也反映了市场对于高质量创新药项目的认可。近几年创新药获得多方面的政策支持，2024年7月国常会审议通过《全链条支持创新药发展实施方案》，在价格管理，投融资，审评审批，医保支付等方面支持产业发展。北京、广州等地也纷纷出台政策，设立产业投资基金，为创新药发展注入资金。政策大力支持下，越来越多国产创新药不断取得优效数据，获得全球产业链合作机会。可以预见，在高质量发展大背景下，产业不断升级，中国创新药企将凭借成本，人才，效率等优势在全球药品市场扮演越来越重要角色，中国创新药产业已步入黄金发展期。我们也非常关注创新技术对行业的积极影响，人工智能（AI）为医疗行业带来了数据价值重估，降本增效，商业模式创新等变化。从投资角度而言，医药相关细分行业也因新技术产生变化有了估值体系变化的基础， AI技术的注入犹如为行业插上翅膀，打开更大想象空间。组合配置方向包括创新药、创新器械，生物制品、中药、医疗服务、医药商业、消费品等。我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以中长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","declarationDate":"2025-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.111Z","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"国联医药消费混合型证券投资基金2025年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1276094","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517dbd","date":"2024-12-30T16:00:00.000Z","stockId":3000000015032,"sao":"2024年医药行业仍然受到整体经济环境和医疗集中整治行动扰动，大部分院内和OTC渠道产品销售情况不及市场年初较为乐观的预期。部分可选消费行业需求端相对疲软。政策层面支持创新相关文件陆续出台，新质生产力将成为经济发展新动能。组合以医药生物为核心配置，较多权重配置创新药，其他方向包括创新器械，消费品等。我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以中长期视角构建组合，努力为持有人创造长期回报。","declarationDate":"2025-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.108Z","mo":"预计美国通胀边际变化将影响市场对美联储降息节奏预期，关税政策调整提升对美国经济不确定性。国内方面，稳增长相关经济政策会适时推出用应对内外部环境变化。预计国内资本市场流动性边际改善，风险偏好有所提升。国家层面多次表达大力支持科技创新推动产业升级的决心，我们对后续政策工具的操作空间和持续性充满信心。新技术如人工智能（AI）对产业效率提升将引发多个领域新增价值发现。2025年医药行业投资机会值得期待，AI技术的进步将引发医疗行业多个领域的深刻变革，提升研发和服务效率，诊断准确性，催生新的产品和商业模式也将随之而来。从投资角度而言，医药相关细分行业也因新技术产生变化有了估值体系变化的基础，在医药板块经历了近四年时间调整处于历史相对低位的背景下，AI技术的注入犹如为行业插上翅膀，打开更大想象空间。AI+医疗将衍生较多投资机会。除此之外，创新药领域亦值得持续关注，2024年以来国家和地方管理部门多次发文支持创新药产业发展，预计2025年商业保险更多融入支付体系呈现多元化支付以及医保目录分类变化都将使得创新药受益。","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"国联医药消费混合型证券投资基金2024年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1246897","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517dbc","date":"2024-09-29T16:00:00.000Z","stockId":3000000015032,"sao":"2024年美联储9月公布降息50个基点。后续货币政策节奏仍需围绕通胀，非农就业数据等指标。欧元区经济增长动能仍然偏弱，部分国家面临衰退风险。国内方面，9月下旬央行等多部门提出的政策组合拳有效提振了市场信心，近期政治局会议也明确传递了通过逆周期调节来稳增长的积极信号，后续财政方案细节和支持方向值得关注。行业层面，医药制造业经营收入和利润进入三季度以来数据边际改善。去年开始的集中反腐行动对处方端仍有一定影响，如院内药品销售，设备进院等。年初市场对终端恢复进程有较乐观预期，实际经营数据在相关板块和个股调整中不断修正。从长期视角来看，医疗产业需求增长逻辑不变，处方行为更以治疗刚需和质量为导向，行业规范行动以短痛换得长期健康发展。可以预期很多子行业陆续出现经营改善。国家层面提出的大力发展新质生产力将加速经济转型过程中新旧动能切换，政策支持下，创新药品，创新药器械有望获得更多实质支持，相关配套产业链经过供给优化后有望迎来新一轮景气周期。积极货币和财政政策有利于提升消费者信心，医疗服务和医药商业相对受益。生物制品，中药，消费品等方向仍将保持关注。本产品聚焦医药生物，消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","declarationDate":"2024-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.106Z","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"国联医药消费混合型证券投资基金2024年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1178468","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517dbb","date":"2024-06-29T16:00:00.000Z","stockId":3000000015032,"sao":"回顾上半年市场情况，医药板块处于震荡调整阶段，低风险偏好风格如国央企和部分低估值中药相对表现较好。预计下半年反腐扰动减弱，院内部分细分方向业绩趋势有望改善。如果年内美联储货币政策转向，外部边际变化有利于提升风险偏好。我们重点关注创新药和创新器械方向，今年以来管理部门陆续推出支持政策，相关产品后续有望在审批，进院，支付等多方面体现优势。经过融资和行业调整期后，创新药供给侧优化，重磅产品陆续落地带动产业进入快速发展期。高壁垒创新器械在设备更新和基数突破背景下，有望加速进口替代和国际化。其他关注方向包括部分生物制品、中药、医疗服务、医药商业、消费品等。我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以中长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","declarationDate":"2024-07-18T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.103Z","mo":"2024年二季度海外市场美国经济表现出一定的韧性，通胀温和回落，财政支出起到调节作用。欧洲央行6月宣布降息后，欧元区经济增长和通胀水平仍有不确定性。国内方面，在积极推进高质量发展背景下，二季度经济延续缓慢复苏趋势。预计2024年下半年美国仍向经济软着陆方向努力，美联储货币政策转向时点具有不确定性。国内产业政策支持将持续引导经济结构调整，预计货币政策趋于稳定，防风险工具充裕。证券市场今年以来风险偏好较低，高股息等防御属性成为重要考量指标。市场处于低位对内部和外部增量资金吸引力增强，存量为主格局有望迎来边际改善，产业政策支持方向仍然值得重点关注。行业层面，医药板块五月份以来震荡调整体现了市场对二季度行业景气的悲观预期，我们需要理性评估风险收益机会。目前医药基本面，估值，机构持仓处于“三低”状态，以院内治疗相关子行业为例，很多细分方向下半年基数边际走弱叠加需求恢复，业绩趋势有望逐季改善。目前医药板块估值处于十年维度相对底部区间，结合持仓水平较低，板块已具备较高吸引力。","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"国联医药消费混合型证券投资基金2024年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1146795","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517dba","date":"2024-03-30T16:00:00.000Z","stockId":3000000015032,"sao":"2024年一季度海外市场美国经济温和增长，居民消费和政府投资仍然起到重要支撑作用。欧元区经济增长相对较弱，部分负面因素边际改善，等待货币政策转向。年初以来国内政策积极，《政府工作报告》中提出加快发展新质生产力，新旧动能切换过程中目标明确。预计2024年二季度美国通胀水平仍然受到能源和金属价格波动影响出现反复，美联储货币政策转向时点不确定性增强。国内经济方面，产业政策支持有望逐步引导内生增长温和复苏，预计货币政策趋稳，有充裕空间应对变化。行业层面，医药行业进入中长期维度较好的配置时点，2021年中期以来医药板块经历了两年多调整，2023年三季度反腐让市场进一步释放悲观情绪，短期处方端商务和推广活动扰动造成的供需错位并不影响需求增长的确定性，行业生态变革对中长期健康发展是利好的，供给端优化后处方行为更加趋向合理有效。我们从科技创新，国际化，老龄化几个维度可以寻找相应的投资机会。我们重点看好创新药方向，政策鼓励下，我们认为后续大概率在审批端，进院，支付端等多方面得到实质性支持。经过融资和行业周期调整后，创新药的供给侧进行了有效的优化，全球创新药重磅产品陆续实现突破带动产业进入新一轮发展时期，国内创新药经历多年积累也步入收获期，相信在减重领域，ADC，双抗，基因治疗，核酸药物等领域技术突破带动产业快速发展。其他方向重点关注医疗器械、医疗服务、医疗消费、医药零售、可选消费品等。我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以中长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","declarationDate":"2024-04-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.100Z","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"国联医药消费混合型证券投资基金2024年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1069758","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517db9","date":"2023-12-30T16:00:00.000Z","stockId":3000000015032,"sao":"医药板块从2021年中期的相对高位经历了两年多调整，2023年三季度以来的行业反腐行动让市场进一步释放了悲观情绪。短期处方端商务和推广活动扰动造成的供需错位并不影响需求增长的确定性，反而对行业中长期发展是利好的，供给端优化后处方行为更加趋向合理有效。展望2024年，我们从科技创新，国际化，老龄化几个维度寻找相应的投资机会。消费品领域，2023年年初市场对经济活动恢复带动的消费回暖期待较高，从二季度到四季度的数据表现来看，恢复较为缓慢且出现结构性变化。目前市场预期并不算高，实际的复苏情况需要跟踪相关数据，2024年仍然对消费的边际变化充满信心。行业层面，重点关注医疗器械、创新药产业链、医疗服务、医疗消费、医药零售、消费品等。同时，我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以中长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","declarationDate":"2024-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.098Z","mo":"2023年海外市场美国经济展现出较好的韧性，四季度按年率计算更是取得3.3%增长，政府加财政杠杆和居民超额储蓄消费是主要因素。预计美联储将进一步评估经济情况和通胀水平以实施后续货币政策，目前美联储利率区间5.25%-5.5%较高水平，虽然没有明确降息时间表，但高利率持续时间过长而带来的风险将成为重要的考量因素。国内政策仍然以稳为主，居民主动去杠杆使得消费恢复较为缓慢，相信财政政策具备充裕工具和空间来实现稳中求进的目标。展望2024年，美国经济动能大概率走弱，能源价格仍然是影响通胀的不确定因素，美联储货币政策大概率转向宽松。国内经济方面，部分出口品类受益于海外补库存周期，投资端预计财政加大力度倾向民生领域，消费处于复苏趋势中。在高质量发展的大背景下，具备较强科技属性的新兴产业的边际变化和政策指引更重于静态数据。","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"国联医药消费混合型证券投资基金2023年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1055700","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517db8","date":"2023-09-29T16:00:00.000Z","stockId":3000000015032,"sao":"2023年三季度全球市场需求和供给持续承压，美国经济表现出较好的韧性，消费起到重要作用。能源价格上涨使得美国通胀压力提升，美联储加息节奏放缓，不排除美联储仍可能进一步加息。国内三季度经济企稳趋势明显，我们对于经济复苏积极乐观，相信财政政策具备充裕工具和空间来实现稳中求进的目标。展望四季度，海外需求仍然偏弱，消费对美国经济带动作用减弱，能源价格波动具有较强不确定性，美元指数上行空间有限。国内经济复苏的势能在增强，出口具备结构调整的条件，投资端预计财政加大力度倾向于民生领域，消费信心恢复和意愿提升将带动终端数据逐步改善。在高质量发展的大背景下，具备较强科技属性的新兴产业的边际变化和政策指引更重于静态数据。行业层面，重点关注自主科技创新和经济活动恢复相关的创新药产业链、医疗器械、医疗服务、医疗消费、二类疫苗、零售渠道、可选消费品等。同时，我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以中长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","declarationDate":"2023-10-23T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.094Z","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"国联医药消费混合型证券投资基金2023年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=984502","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517db7","date":"2023-06-29T16:00:00.000Z","stockId":3000000015032,"sao":"上半年市场结构性行情演绎较为显著，行业表现分化，基金配置在重点方向权重有一定倾斜。后续国内经济数据边际改善和增量资金进入市场值得期待。医药行业目前处于中长期较好布局时点，值得重点关注。子行业层面，重点关注自主科技创新和经济活动恢复相关的医疗器械、创新药产业链、医疗服务、医疗消费、二类疫苗、零售渠道、可选消费品等。同时，我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以中长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","declarationDate":"2023-07-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.091Z","mo":"2023年上半年全球通胀回落但仍处于较高水平，美联储加息节奏放缓，在通胀压力没有大幅缓解情况下，不排除进一步加息可能，预计空间有限。国内一季度积压需求释放带动经济数据回暖提升了市场对复苏的强预期，二季度经济动能减弱，复苏较为缓慢，我们对于经济复苏并不悲观，相信财政政策具备充裕工具和空间来实现稳中求进的目标。预计2023年下半年海外需求仍然偏弱，国内经济复苏的动能大概率边际走强。出口贸易因结构调整将展现较强的韧性，投资方面预计财政资金更加倾向于民生领域，消费信心恢复和意愿提升将带动终端数据逐步改善。在高质量发展的大背景下，具备较强科技属性的新兴产业的边际变化和政策指引更重于静态数据。另外，重点关注医药行业政策对产业趋势中长期影响及消费行业需求变化趋势。","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"中融医药消费混合型证券投资基金2023年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=959687","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517db6","date":"2023-03-30T16:00:00.000Z","stockId":3000000015032,"sao":"2023年一季度美国通胀逐步回落，美联储持续加息使得经济衰退风险累积。国内经济活动恢复背景下，内需复苏较为温和，相比外需体现较强韧性，财政政策具备充裕工具和空间来实现稳中求进的目标。预计2023年二季度外围经济环境走弱的环境下，外贸承压，国内产业链复苏程度有所分化。能源价格回落有利于缓解中下游产业成本压力，制造业部分环节仍将去化过剩产能，终端消费将逐步改善。具备较强科技属性的新兴产业的边际变化和政策指引更重于静态数据。行业层面，重点关注自主科技创新和经济活动恢复相关的医疗器械、创新药产业链、医疗服务、医疗消费、二类疫苗、零售渠道、可选消费品等。同时，我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以中长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","declarationDate":"2023-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.089Z","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"中融医药消费混合型证券投资基金2023年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=884668","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517db5","date":"2022-12-30T16:00:00.000Z","stockId":3000000015032,"sao":"自2022年9月医药板块触及10年时间维度的相对低位以来，整个板块由创新药带动走出一波上行趋势。我们通常以基本面和政策为基础，预期细分赛道景气度，盈利趋势等，而估值对于中长期是较为重要的参考指标。随着院内诊疗量的恢复，零售和服务的客流增加，自主科技创新的推进，很多行业和公司的基本面有望持续改善，我们或已站在新一轮医药牛市的初期。防疫政策的放开，消费有望逐步修复。经济活动的活跃及居民超额储蓄的释放潜力，未来消费有望进一步得到提振。行业层面，重点关注疫情后复苏，自主科技创新相关的医疗器械、医疗服务、医疗消费、创新药产业链、二类疫苗、零售渠道、可选消费品等。同时，我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","declarationDate":"2023-01-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.086Z","mo":"2022年海外经济下行压力增加，四季度美国通胀回落，美联储加息节奏放缓。全球发达经济体制造业PMI趋于回落，经济衰退风险进一步暴露。国内新冠疫情管控放松后，经历了短期快速扩散的扰动，但为经济修复打下了坚实的基础，预计终端消费需求将逐步改善。中央经济工作会议强调了“稳增长、稳就业、稳物价”的工作重点，坚持稳中求进的总基调，预计财政政策也将在防风险和稳增长间适度平衡。展望2023年，预计在外围经济走弱的环境下，出口将受一定的影响，国内的投资将适时发力。消费有望迎来改善。从产业链维度来看，部分上游资源品和大宗商品已经从高位回落，中下游产业成本压力有望进一步改善。我们认为，相比于海外，国内经济更具韧性且国内政策工具充裕可以应对变化。","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"中融医药消费混合型证券投资基金2022年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=868188","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517db4","date":"2022-09-29T16:00:00.000Z","stockId":3000000015032,"sao":"2022年三季度海外高通胀环境下美联储继续收紧货币流动性，全球经济衰退风险临近。国内近期仍有新冠疫情散点发生，但科学有效的管控方法很好的遏制了疫情扩散，没有出现大面积传染。如后续疫情不再扰动，终端需求或将逐步改善。近期国务院召开经济会议强调继续实施好稳定经济的一揽子政策并推出政策性开发金融工具和财政贴息等政策工具，预计年内国内货币段仍维持较为宽松的局面。展望四季度，在外围经济走弱的环境下，国内的出口和制造业将受一定的影响，然而消费有望迎来改善。从产业链维度来看，部分上游资源品和大宗商品较难延续强势，中下游产业成本压力有望改善。相比于海外，国内经济更具韧性且国内政策工具充裕可以应对变化。行业层面，重点关注疫情后复苏主线相关的医疗器械、医疗服务、医疗消费、二类疫苗、创新药、零售渠道、可选消费品等。同时，我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","declarationDate":"2022-10-25T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.083Z","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"中融医药消费混合型证券投资基金2022年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=810805","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed1177fea5b3eb0517db3","date":"2022-06-29T16:00:00.000Z","stockId":3000000015032,"sao":"2022年二季度美联储继续收紧货币流动性，美国经济下行预期增强。国内新冠疫情散点扩散，制造业和消费受到了一定程度的扰动。随着我国应对疫情工具丰富及管控方法更加科学合理，预计后续疫情对国内经济影响边际改善。另外，从M2和社融规模存量同比变化趋势可以看到，2022年5，6月份国内货币流动性较充裕，市场也呈现出较好表现。行业层面，重点关注疫情后复苏主线相关的医疗服务、医疗消费、、二类疫苗、创新药、医疗器械、零售渠道、可选消费品等。同时，我们顺应产业趋势经过行业比较选择高景气领域，结合投资框架、调研、分析精选个股，以长期视角构建组合。本产品聚焦医药生物、消费品领域，以医药生物为核心配置。我们将努力为持有人创造长期回报。","declarationDate":"2022-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:54:31.080Z","mo":"展望下半年，预计稳增长正常持续发力，部分上游资源品和大宗商品较难延续强势，中下游成本压力有望改善。如果外围经济走弱，国内经济相对更有韧性且国内货币工具充裕可以应对变化。持续关注疫情后医药、消费和服务业的景气恢复情况。","fund":{"_id":3000000015032,"__csrcFundId":10856,"stockCode":"015032","shortName":"国联医药消费混合(015032)","masterFundShortName":"国联医药消费混合","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":15032,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-05-01T00:27:33.331Z","status":"normal","exchange":"jj","name":"国联医药消费混合型证券投资基金","fundCollectionId":4000050820000,"inceptionDate":"2022-03-08T16:00:00.000Z","followedNum":10,"setUpDate":"2022-03-08T16:00:00.000Z","setUpAssetScale":175066150.86,"setUpShares":175066150.86,"pinyin":"glyyxfhhxzqtzjj","managers":[{"stockCode":"f100000022","stockType":"fund_manager","exchange":"fm","tickerId":162017207010,"name":"潘天奇"}]},"announcement":{"linkText":"中融医药消费混合型证券投资基金2022年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=783365","linkType":"PDF","source":"csrc_pdf"}}]}